| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.974 auroc unitless · higher Uncertainty: 95% CI 0.9673 to 0.9796 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C15; group 'BRCA'; row 'FSR'; column 'AUC' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.897 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.8721 to 0.9226 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E15; group 'BRCA'; row 'FSR'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.771 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.7332 to 0.8088 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D15; group 'BRCA'; row 'FSR'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.951 auroc unitless · higher Uncertainty: 95% CI 0.9390 to 0.9636 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C25; group 'CHOL'; row 'FSR'; column 'AUC' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.768 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.7110 to 0.8256 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E25; group 'CHOL'; row 'FSR'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.667 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.6070 to 0.7264 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D25; group 'CHOL'; row 'FSR'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.987 auroc unitless · higher Uncertainty: 95% CI 0.9798 to 0.9941 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C35; group 'CRC'; row 'FSR'; column 'AUC' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.953 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.9293 to 0.9774 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E35; group 'CRC'; row 'FSR'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.935 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.9058 to 0.9642 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D35; group 'CRC'; row 'FSR'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2)
Dataset: Jiang et al. 2018 plasma WGS, 90 liver cancer and 135 non-cancer (as used by Hou et al. 2024) | 0.936 auroc unitless · higher Uncertainty: 95% CI 0.9263 to 0.9455 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Jiang cohort liver cancer cross-validation ctdnafrag-20261009-protocol-hou2024-jiang-lihc-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C85; group 'LIHC'; row 'FSR'; column 'AUC' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.945 auroc unitless · higher Uncertainty: 95% CI 0.9163 to 0.9730 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C55; group 'NSCLC'; row 'FSR'; column 'AUC' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.855 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.7896 to 0.9204 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E55; group 'NSCLC'; row 'FSR'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.81 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.7383 to 0.8817 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D55; group 'NSCLC'; row 'FSR'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.993 auroc unitless · higher Uncertainty: 95% CI 0.9899 to 0.9960 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C65; group 'OV'; row 'FSR'; column 'AUC' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.973 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.9539 to 0.9928 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E65; group 'OV'; row 'FSR'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.883 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.8346 to 0.9321 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D65; group 'OV'; row 'FSR'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.841 auroc unitless · higher Uncertainty: 95% CI 0.8109 to 0.8704 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C75; group 'PAAD'; row 'FSR'; column 'AUC' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.672 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.6223 to 0.7210 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E75; group 'PAAD'; row 'FSR'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.569 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.5173 to 0.6211 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D75; group 'PAAD'; row 'FSR'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.944 auroc unitless · higher Uncertainty: 95% CI 0.9369 to 0.9513 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C5; group 'PANCAN'; row 'FSR'; column 'AUC' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.959 auroc unitless · higher Uncertainty: 95% CI 0.9401 to 0.9788 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C45; group 'STAD'; row 'FSR'; column 'AUC' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.903 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.8646 to 0.9420 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E45; group 'STAD'; row 'FSR'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.848 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.8030 to 0.8936 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D45; group 'STAD'; row 'FSR'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024) | 0.691 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG) ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C15; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'FSR'; column 'AUC' |
|---|
| Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024) | 0.38 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceFSR (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG) ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E15; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'FSR'; column 'Sensitivity @85% specificity' |
|---|